Skip to main content

Diagnostic and Prognostic Value of Plasma Levels of Cardiac Myosin Binding Protein-C as a Novel Biomarker in Heart Failure

Pediatric Cardiology volume 38, pages 418–424 (2017)Cite this article

Abstract

Heart failure (HF) has high morbidity and mortality in children. This study aimed to investigate the value of cardiac myosin binding protein-C (cMyBP-C) as a diagnostic and prognostic biomarker in children with heart failure. This study was a prospective case–control study that involved 50 children with acute HF and 25 healthy children of matched age and sex as a control group. cMyBP-C plasma levels were measured in patients with HF at the time of admission and 1 month after treatment. Echocardiographic assessment was done for all children. All patients were followed up for a period of 3 months. There was a significant increase in plasma levels of cMyBP-C (ng/ml) in patients with HF at admission (122.44 ± 41.01) as compared to patients after treatment (71.38 ± 49.68) and to control group (24.40 ± 9.83). This increase was associated with increased severity of HF according to pediatric Ross classification of HF. Significant increase in plasma levels of cMyBP-C at admission and its persistent increase after treatment were associated with adverse outcome of mortality and readmission. Plasma levels of cMyBP-C were significantly correlated with echocardiographic and clinical assessment of heart failure. Plasma levels of cMyBP-C were a good biomarker for diagnosis of HF with sensitivity 100% and specificity 96% at cutoff point of 45 ng/ml. Its value in predicting adverse outcome in HF patients was obtained by ROC curve with sensitivity of 90% and specificity 93% at a cutoff point of 152 ng/ml cMyBP-C at admission. cMyBP-C may be a novel useful diagnostic and prognostic biomarker in children with heart failure and determination of severity of HF in these patients.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. Rossano JW, Kim JJ, Decker JA, Price JF, Zafar F, Graves DE, Morales DL et al (2012) Prevalence, morbidity and mortality of heart failure related hospitalization in children in the Unites States: a population based study. J Card Fail 18:459–470

    Article  PubMed  Google Scholar 

  2. Juenger J, Schellberg D, Kraemer S et al (2002) Health related quality of life in patients with congestive heart failure: comparison with other chronic diseases and relation to functional variables. Heart 87(3):235–241

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  3. Hickman PE, Potter JM (2003) New cardiac markers. Aust Prescr 26:88–90

    Article  Google Scholar 

  4. Cohen-Solal A, Laribi S, Ishihara S, Vergaro G, Baudet M, Logeart D, Mebazaa A, Gayat E, Vodovar N, Pascual-Figal DA, Seronde MF (2015) Prognostic markers of acute decompensated heart failure: the emerging roles of cardiac biomarkers and prognostic scores. Arch Cardiovasc Dis 108:64–74

    Article  PubMed  Google Scholar 

  5. Copeland O, Sadayappan S, Messer AE, Steinen GJM, van der Velden J, Marston SB (2010) Analysis of cardiac myosin binding protein C phosphorylation in human heart muscle. J Mol Cell Cardiol 49(6):1003–1011

    CAS  Article  PubMed  Google Scholar 

  6. Barefield D, Sadayappan S (2010) Phosphorylation and function of cardiac myosin binding protein-C in health and disease. J Mol Cell Cardiol 48(5):866–875

    CAS  Article  PubMed  Google Scholar 

  7. El-Armouche A, Pohlmann L, Schlossarek S, Starbatty J, Yeh YH, Nattel S, Dobrev D, Eschenhagen T, Carrier L (2007) Decreased phosphorylation levels of cardiac myosin binding protein C in human and experimental heart failure. J Mol Cell Cardiol 43(223):229

    Google Scholar 

  8. Govindan S, Kuster DWD, Lin B, Jeske WP, Walenga JM, Leya F, Hoppensteadt D, Fareed J, Sadayappan S (2013) Increase in cardiac myosin binding protein C plasma levels is a sensitive and cardiac specific biomarker of myocardial infarction. Am J Cardiovasc Dis 3(2):60–70

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Govindan S, McElligott A, Muthusamy S, Nair N, Barefield D, Martin JL, Gongora E, Greis KD, Luther PK, Winegrad S, Henderson KK, Sadayappan S (2012) Cardiac myosin binding protein-C is a potential diagnostic biomarker for myocardial infarction. J Mol Cell Cardiol 52(1):154–164

    CAS  Article  PubMed  Google Scholar 

  10. Ross RD, Daniels SR, Schwartz DC, Hannon DW, Shukla R, Kaplan S (1987) Plasma levels of norepinephrine in infants and children with congestive heart failure. Am J Cardiol 59:911–914

    CAS  Article  PubMed  Google Scholar 

  11. McMurray JJ (2010) Clinical practice. Systolic heart failure. N Engl J Med 362:228–238

    CAS  Article  PubMed  Google Scholar 

  12. Sato Y, Fujiwara H, Takatsu Y (2012) Biochemical markers in heart failure. J Cardiol 59(1):1–7

    Article  PubMed  Google Scholar 

  13. Jeong EM, Zhou L, Xie A, Liu M, Zhou A, Liu H, Liu D, Shi G, Dudley S (2015) Heart failure and cardiomyopathies. JACC 65(10S):993

    Article  Google Scholar 

  14. Sadayappan S, Osinska H, Klevitsky R, Lorenz JN, Sargent M, Molkentin JD, Seidman CE, Seidman JC, Robbins J (2006) Cardiac myosin binding protein C phosphorylation is cardioprotective. Proc Natl Acad Sci USA 103:16918–16923

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  15. Razzaque MA, Gupta M, Osinska H, Gulick J, Blaxall BC, Robbins J (2013) An endogenously fragment of the cardiac myosin-binding protein C is pathogenic and can lead to heart failure. Circ Res 113(5):553–561

    CAS  Article  PubMed  Google Scholar 

Download references

Author information

Affiliations

  1. Pediatric Department, Tanta University Hospital, El Motasem Street, Tanta, Egypt

    Doaa El Amrousy & Nahed Hablas

  2. Clinical Pathology Department, Tanta University Hospital, Tanta, Egypt

    Hossam Hodeib & Ghada Suliman

  3. Anesthesiology and ICU Department, Tanta University Hospital, Tanta, Egypt

    Eman Ramadan Salama & Ahmed Esam

Authors
  1. Doaa El Amrousy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hossam Hodeib
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ghada Suliman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nahed Hablas
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Eman Ramadan Salama
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ahmed Esam
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Doaa El Amrousy.

Ethics declarations

Conflict of interest

All authors have no potential conflict of interest to disclose.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

El Amrousy, D., Hodeib, H., Suliman, G. et al. Diagnostic and Prognostic Value of Plasma Levels of Cardiac Myosin Binding Protein-C as a Novel Biomarker in Heart Failure. Pediatr Cardiol 38, 418–424 (2017). https://doi.org/10.1007/s00246-016-1532-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00246-016-1532-2

Keywords

  • cMyBP-C
  • Heart failure
  • Children